CN1296825A - Capsule or tablet for treating viral hepatitis - Google Patents

Capsule or tablet for treating viral hepatitis Download PDF

Info

Publication number
CN1296825A
CN1296825A CN00113931A CN00113931A CN1296825A CN 1296825 A CN1296825 A CN 1296825A CN 00113931 A CN00113931 A CN 00113931A CN 00113931 A CN00113931 A CN 00113931A CN 1296825 A CN1296825 A CN 1296825A
Authority
CN
China
Prior art keywords
radix
tablet
treatment
capsule
viral hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN00113931A
Other languages
Chinese (zh)
Other versions
CN1137701C (en
Inventor
谢康让
谢庞飞
谢红娟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
XIE RANGFEI
Original Assignee
XIE RANGFEI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by XIE RANGFEI filed Critical XIE RANGFEI
Priority to CNB001139312A priority Critical patent/CN1137701C/en
Publication of CN1296825A publication Critical patent/CN1296825A/en
Application granted granted Critical
Publication of CN1137701C publication Critical patent/CN1137701C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A Chinese medicine in the form of capsule or tablet for treating viral hepatitis, recovering liver function and relieving liver or spleen swelling is prepared from 12 Chinese-medicinal materials including turtle shell, ground beetle, ginseng, belamcanda rhizome, peach kernel, etc through preparing raw materials, purifying and capsulizing or tabletting. Its advantages are high curative effect on viral hepatitis, fatty liver and hepatitises A, B, C and E.

Description

A kind of capsule or tablet for the treatment of viral hepatitis
The present invention relates to a kind of capsule and tablet for the treatment of viral hepatitis, original name GANLIKANG JIAONANG, GANLIKANG PIAN.
In background technology, sell tablet medicines such as ZANGYINCHEN sheet, liver-protecting tablet on the market, all based on the treatment hepatopathy; In " Chinese invention patent communique ", " Chinese medicine " Margarita Huibiedan " of treatment hepatitis B " was disclosed on November 26th, 1997, purpose is to kill hepatitis B virus, promote that liver function recovery is normal, medicine has 16 flavor medicines such as Margarita, Aloe, Semen Momordicae frost, Carapax Trionycis, pyrolusitum, golden Radix Bupleuri, through infusion technology, make capsule preparations.Above-mentioned treatment hepatopathy all has their own characteristics each.
The objective of the invention is to develop a kind of capsule or tablet for the treatment of viral hepatitis, eliminate hepatosplenomegaly, removing blood stasis is attacked the stasis of blood, softening hardness and resolving stasis, the toxin expelling of invigorating blood circulation, reinforcement and elimination in combination, regulate body immunity, the control virus replication improves the liver detoxification ability, promote hepatic tissue to recover and regeneration, reach the treatment viral hepatitis, recover liver function, remove hepatosplenomegaly, hepatitis B virus serum thing is turned out cloudy and can make the purpose of hepatitis A, hepatitis C, hepatitis D, the clear antibody male rotary the moon of the eleventh of the twelve Earthly Branches liver blood.
Technical solution of the present invention is as follows:
Medicine source, side: component of the present invention is the classical prescription " Carapax Trionycis ball " of Treatise on Febrile and Miscellaneous Disease, cures mainly malaria with the passing of time, and fullness and rigidity in the hypochondrium has piece, becomes malaria with splenomegaly; Form and contain Carapax Trionycis, Rhizoma Belamcandae, Radix Scutellariae, Radix Bupleuri, Armadillidium, Rhizoma Zingiberis, Radix Et Rhizoma Rhei, Radix Paeoniae, Cortex cinnamomi japonici (Ramulus Cinnamomi), booth power seed, Folium Pyrrosiae, Cortex Magnoliae Officinalis, Paeonia suffruticosa, Dianthus superbus L., purple prestige, the Rhizoma Pinelliae, Radix Ginseng, eupolyphaga, Colla Corii Asini, beehive, red nitre, Catharsii molossi, Semen Persicae, 23 flavor Chinese herbal medicine, reinforcement and elimination in combination in the side, generous for the removing mass blood stasis dispelling.
The present invention is the change sanction side of above-mentioned " Carapax Trionycis ball ", gets wherein Carapax Trionycis, eupolyphaga, Rhizoma Belamcandae, Semen Persicae, Radix Paeoniae, Radix Ginseng, Radix Scutellariae, Cortex Moutan 8 flavors and adds the Rhizoma Atractylodis Macrocephalaes, my art, pool a kind of reed mentioned in ancient books, Radix Gentianae 4 flavors and form 12 flavors.
Medicine material weight percent content: Carapax Trionycis processed with vinegar 6-14%, eupolyphaga 10-15%, Radix Ginseng 4-6%, Rhizoma Belamcandae 6-10%, Semen Persicae 6-10%, Radix Paeoniae Alba 6-10%, Radix Scutellariae 8-12%, Radix Gentianae 8-12%, unpeeled CORTEX MOUTAN 8-12%, my art 10-15%, pool Siberian cocklebur 10-15%, Rhizoma Atractylodis Macrocephalae 10-15%, getting each component sum is 100%;
Preparation method: raw material is prepared: get above-mentioned eupolyphaga, Rhizoma Belamcandae, Semen Persicae, the Radix Paeoniae Alba, Radix Scutellariae, Radix Gentianae, unpeeled CORTEX MOUTAN, my art, pool Siberian cocklebur, Rhizoma Atractylodis Macrocephalae raw material, and stand-by after processing purifies; Purify:, purify, filter, reduce pressure, be concentrated into relative density 1.3 grams~1.5 gram per centimeters through refluxing above-mentioned material precentagewise weight proportion 3Thick paste, add Carapax Trionycis processed with vinegar and Radix Ginseng powder's mix homogeneously of weight percent; Make:, make a capsules preparation or a tablet preparation by 0.5 gram medicine through vacuum drying.
Advantage of the present invention and effect: 1, good through clinical therapeutic efficacy.Matched group 106 examples, 105 examples are organized in treatment; The treatment standard: glutamate pyruvate transaminase, glutamic oxaloacetic transaminase, GOT, alkali phosphatase, total bilirubin, the high value of bilirubin direct, all the arm's length standard scope of formulating with Ministry of Public Health is as the criterion.Through clinical treatment 3 months was a course of treatment, total inspection 6 months; The medication process: matched group adopts anti-hepatitis B immune ribonucleic acid; Each 4mg, the next day once, intramuscular injection, three months is a course of treatment; Oral vitamin B6 measures 0.2g simultaneously, vitamin C amount 0.3g, and inosine 0.4g, every day three times, every month chemical examination liver function is once; Capsule 0.5 gram that the treatment group is made with the present invention, three times every month, each 6,3 months is a course of treatment, every month chemical examination liver function is once.Serological testing: for the anti-source HBSAg in surface, the anti-source HBEAg of E, the anti-source HBCAg of core turns out cloudy simultaneously, and 11 examples are organized in treatment, matched group 2 examples; Turn out cloudy for anti-HBE, 34 examples are organized in treatment, matched group 4 examples; Turn out cloudy for HBEAg, HBCAg, 6 examples are organized in treatment, matched group 2 examples; HBSAg turns out cloudy, and 5 examples are organized in treatment, matched group 1 example; HBSAg, anti--HBE, anti-HBC turn out cloudy, and 6 examples are organized in treatment, matched group 1 example; Total effectively negative conversion rate treatment group 58.4%, matched group 9.4%.
Curative effect: treatment group: after 6 months, liver function is cured 84 examples, produce effects 17 examples, effective 2 examples, invalid 3 examples.Total effectively negative conversion rate 58.4%.
Matched group: after 6 months, liver function is cured 39 examples, produce effects 23 examples, and effective 24 examples, invalid 19, total effectively negative conversion rate 9.4%.
2, through clinical treatment, treatment group cure rate is greater than 79%, total effective rate 98%, matched group cure rate 37%, total effective rate 81.9%; In the treatment group, total bilirubin TB, bilirubin direct DB, glutamate pyruvate transaminase ALT, glutamic oxaloacetic transaminase, GOT, alkali phosphatase ALP have notable difference, liver function to recover obviously excellent and matched group of normal person more than 4 weeks fully before and after the treatment.It is weak to cure mainly the patient, uncomfortable liver area or pain, and dyspepsia, liver is painful, and the matched group hepatosplenomegaly does not have effect substantially.
3, the present invention all has curative effect preferably to viral hepatitis, hepatitis A, hepatitis B, hepatitis C, hepatitis E and fatty liver, and clinical practice has no side effect, and the hepatosplenomegaly that can bounce back can make hepatosplenomegaly with obvious elimination or bounce back to normal.To the high value of albumen, albumen value has tangible balanced action.
4, the elimination clinical symptoms is obvious, can regulate body immunity, the control virus replication recovers liver function, improves the liver detoxification ability, promote hepatic tissue to recover and regeneration, can antiinflammatory, function of gallbladder promoting, jaundice eliminating, improve organism metabolism, can the anti-hepatitis B fibrosis, the effect that suppresses liver cirrhosis and hepatocarcinoma is arranged, the serum virus thing is turned out cloudy.To the clinical symptom that produces: weak, dyspepsia, sodium error, hepatalgia, gallbladder merges the secondary inflammation that the obvious treatment effect is arranged, to surface antigen HBSAg, anti-source HBEAg of E or E antibody HBEAb and the anti-source HBSAg of core or core antibody HBCAb can turn out cloudy fully, thoroughly remove hepatitis B virus, three more than the course of treatment, negative conversion rate is higher, three months each courses of treatment.
The embodiment of the invention: get following weight percent: Carapax Trionycis processed with vinegar 6-14%, eupolyphaga 10-15%, Radix Ginseng 4-6%, Rhizoma Belamcandae, Semen Persicae, the Radix Paeoniae Alba respectively are 6-10%, Radix Scutellariae, Radix Gentianae, each 8-12% of unpeeled CORTEX MOUTAN, my art 10-15%, pool Siberian cocklebur 10-15%, Rhizoma Atractylodis Macrocephalae 10-15% gets the each component sum and is a hundred per cent.Be monarch with Carapax Trionycis, eupolyphaga in the side, eliminate hepatosplenomegaly, Semen Persicae, my art, Radix Paeoniae are minister, removing blood stasis is attacked silt, softening hardness and resolving stasis, the toxin expelling of invigorating blood circulation, treating the liver must be invigorated blood circulation, and the toxin expelling of invigorating blood circulation is the main outline of treatment viral hepatitis, removing blood stasis counteracting toxic substances, remove the knot of blood poisoning heresy, liver is a blood bank, is the major organs of blood digestion, assistant is with pool Siberian cocklebur, the Rhizoma Atractylodis Macrocephalae, invigorating spleen and reinforcing stomach, and toxin expelling is gone out, Radix Scutellariae, Radix Gentianae, Rhizoma Belamcandae are the main medicine of heat clearing away toxin expelling, unpeeled CORTEX MOUTAN, Radix Ginseng, the removing heat from blood that purifies the blood, enhance immunity for making.
Preparation method: 1, raw material is prepared: choose clean fresh raw material, and after the processing section purifies, stand-by.2, purify: the above-mentioned raw materials after will purifying is formed proportioning by weight percentage, wherein Carapax Trionycis routinely infusion become the Carapax Trionycis processed with vinegar, it is stand-by that Radix Ginseng was all made 110 mesh sieve powder.With the said medicine mix homogeneously, place to be equipped with still, adding concentration is 60% ethanol, temperature is controlled at 60 ± 5 degree, reflux, extract, 2 times wherein adds for the first time ten to 20 times of amount alcoholic solution backflow secondaries, and the alcoholic solution that adds 6~10 times of amounts for the second time refluxed 1 hour, merging secondary raffinate filters, filtrate decompression is concentrated into the thick paste that relative density 1.3 restrains~1.5 grams per cubic centimters (60 ℃), adds the Carapax Trionycis processed with vinegar, the Radix Ginseng powder mixes, through disinfection by ultraviolet light; Behind the vacuum drying, be prepared into capsule or tablet by 0.5 gram/capsule or 0.5 gram/sheet, once more through disinfection by ultraviolet light, bottling or making sheet.One capsule or a tablet are equivalent to former medicine 2.5~2.6 grams.Above-mentioned technology all can be produced preparation capsule or tablet routinely.

Claims (1)

1, a kind of capsule or tablet for the treatment of viral hepatitis, it is characterized in that: make by following weight percentages, Carapax Trionycis processed with vinegar 6-14%, eupolyphaga 10-15%, Radix Ginseng 4-6%, Rhizoma Belamcandae 6-10%, Semen Persicae 6-10%, Radix Paeoniae Alba 6-10%, Radix Scutellariae 8-12%, Radix Gentianae 8-12%, unpeeled CORTEX MOUTAN 8-12%, my art 10-15%, pool Siberian cocklebur 10-15%, Rhizoma Atractylodis Macrocephalae 10-15%, getting each component sum is 100%;
Preparation method: raw material is prepared: get above-mentioned eupolyphaga, Rhizoma Belamcandae, Semen Persicae, the Radix Paeoniae Alba, Radix Scutellariae, Radix Gentianae, unpeeled CORTEX MOUTAN, my art, pool Siberian cocklebur, Rhizoma Atractylodis Macrocephalae raw material, usefulness such as after processing purifies; Purify: with above-mentioned material precentagewise weight proportion, purify, filter, reduce pressure, be concentrated into the thick paste of relative density 1.3 grams~1.5 grams per cubic centimters through refluxing, add Carapax Trionycis processed with vinegar and Radix Ginseng powder's mix homogeneously of weight percent; Make:, make a capsules preparation or a tablet preparation by 0.5 gram medicine through vacuum drying.
CNB001139312A 2000-09-25 2000-09-25 Capsule or tablet for treating viral hepatitis Expired - Fee Related CN1137701C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB001139312A CN1137701C (en) 2000-09-25 2000-09-25 Capsule or tablet for treating viral hepatitis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB001139312A CN1137701C (en) 2000-09-25 2000-09-25 Capsule or tablet for treating viral hepatitis

Publications (2)

Publication Number Publication Date
CN1296825A true CN1296825A (en) 2001-05-30
CN1137701C CN1137701C (en) 2004-02-11

Family

ID=4583664

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB001139312A Expired - Fee Related CN1137701C (en) 2000-09-25 2000-09-25 Capsule or tablet for treating viral hepatitis

Country Status (1)

Country Link
CN (1) CN1137701C (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1985902B (en) * 2005-12-22 2010-08-25 顾伟民 Chinese medicine for treating chronic hepatopathy

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1985902B (en) * 2005-12-22 2010-08-25 顾伟民 Chinese medicine for treating chronic hepatopathy

Also Published As

Publication number Publication date
CN1137701C (en) 2004-02-11

Similar Documents

Publication Publication Date Title
CN102078473B (en) Traditional Chinese medicine preparation for treating chronic hepatitis b and preparation method thereof
CN100349597C (en) Chinese medicinal preparation for treating virus myocaraitis, its preparation method and quality control method
CN100515482C (en) Chinese traditional medicine for treating acute and chronic hepatitis
CN104208581A (en) Schisandra chinensis health care oral liquid capable of preventing alcoholic liver and preparation method thereof
CN103223131B (en) Liver disease drug
CN1178675C (en) Toxin-discharging liver-fortifying medicine
CN113679794A (en) Uric acid-reducing sunflower disc composition and preparation method thereof
CN102698207A (en) Traditional Chinese medicine composition for treating hepatopathy and preparation method thereof
CN101249255B (en) Proprietary Chinese medicine for curing children's cough and method of preparing the same
CN1137701C (en) Capsule or tablet for treating viral hepatitis
CN101987156B (en) Medicine for treating toothache and preparation method thereof
CN1557354A (en) Chinese medicine aqueous pill preparation for treating hepatitis B and its preparation process
CN1440804A (en) Antilipemic Chinese medicine
CN103800580A (en) Traditional Chinese medicinal prescription for treating adenoidal hypertrophy and preparation method thereof
CN100402065C (en) Capsule for treating gout and preparation process thereof
CN106138785A (en) One treats neurasthenic Chinese medicine composition and preparation method thereof
CN1059104C (en) Capsule for anti hepatitis B
CN1079262C (en) Pregnancy promoting medicine to treat man's and woman's sterility and its preparation
CN101278982A (en) Chinese medicine compound preparation for curing acute or chronic hepatitis B and method of preparing the same
CN110946950A (en) A Chinese medicinal composition for treating senile vascular dementia, and its preparation method
CN1480161A (en) Preparation of Chinese herbal medicine for treating lithiasis as well as its preparing method
CN114617934B (en) Detoxifying and whitening soup
CN103977243B (en) A kind of medicine for treating uremia refractory pruritus and preparation method thereof
CN102406906A (en) Traditional Chinese medicine composition for treating acute hepatitis B
CN102772665B (en) Traditional Chinese medicine preparation for treating yin deficiency and internal heat type vital myocarditis and preparation method thereof

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee